Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 08:44:15 17/07/2024 pm IST			5-day change	1st Jan Change
1.305 ^USD	-1.88%		-1.53%	-7.86%

15/07	Sector Update: Health Care Stocks Edge Lower Late Afternoon	MT
15/07	Sector Update: Health Care Stocks Retreat Monday Afternoon	MT

Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2020

January 14, 2021 at 07:06 pm IST

Artelo Biosciences, Inc. announced earnings results for the first quarter ended November 30, 2020. For the first quarter, the company announced operating loss was USD 1.435 million compared to USD 1.336 million a year ago. Net loss was USD 1.434 million compared to USD 1.306 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.39 a year ago.

Latest news about Artelo Biosciences, Inc.

Sector Update: Health Care Stocks Edge Lower Late Afternoon	16/07	MT
Sector Update: Health Care Stocks Retreat Monday Afternoon	15/07	MT
Artelo Biosciences Gets FDA Clearance for Phase 1 Peripheral Neuropathy Study	15/07	MT
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12	15/07	CI
Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium	03/07	CI
Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform	02/07	CI
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Transcript : Artelo Biosciences, Inc. - Special Call	23/04
Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	23/04	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
Top Premarket Gainers	06/02	MT
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	23/01	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023	02/11	CI
Transcript : Artelo Biosciences, Inc. - Special Call	11/23/11
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Transcript : Artelo Biosciences, Inc. - Special Call	11/23/11
Artelo Biosciences Files $75 Million Mixed Shelf	07/23/07	MT
Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11	07/23/07	CI
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss	02/23/02	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08	CI
Top Premarket Decliners	17/22/17	MT
Top Midday Gainers	16/22/16	MT

Chart Artelo Biosciences, Inc.

Duration

Period

More charts

Company Profile

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.33 USD

Average target price

16.67 USD

Spread / Average Target

+1,153.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARTELO BIOSCIENCES, INC.	-7.86%	42.93L
VERTEX PHARMACEUTICALS INCORPORATED	+18.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+23.05%	12TCr
ARGENX SE	+23.41%	2.79TCr
BIONTECH SE	-18.49%	2.1TCr
GENMAB A/S	-15.13%	1.69TCr
BEIGENE, LTD.	-14.92%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+9.29%	1.48TCr
WUXI APPTEC CO., LTD.	-46.10%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+52.44%	1.41TCr

Bio Therapeutic Drugs